Hitoshi Hagita

发表

Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

T. Fukuzawa, Takamitsu Kobayashi, Y. Kawabe, 2012, Journal of Pharmacology and Experimental Therapeutics.

Microsoft Word-22160437-file00.docx

Takamitsu Kobayashi, Masayuki Suzuki, S. Ikeda, 2012 .

In vitro profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

C. Funk, A. Poirier, Y. Aso, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.

N. Horiba, Y. Ichida, S. Ohtomo, 2020, Kidney international.

5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Motohiro Kato, M. Ohmori, N. Shimma, 2011, Bioorganic & medicinal chemistry.

Fluorescent cytochemical detection of sialidase activity using 5-bromo-4-chloroindol-3-yl-α-D-N-acetylneuraminic acid as the substrate

K. Ikeda, I. Fujii, Y. Iwabuchi, 2002, Histochemistry and Cell Biology.

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

M. Ohmori, Takamitsu Kobayashi, Tsutomu Sato, 2012, Journal of medicinal chemistry.

Age-dependent reduction in sialidase activity of nuclear membranes from mouse brain

R. Yu, S. Ando, M. Saito, 2002, Experimental Gerontology.

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

M. Ohmori, N. Shimma, Takamitsu Kobayashi, 2012, Bioorganic & medicinal chemistry.

In Vitro–In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling Approach

Y. Aso, M. Ishigai, K. Yamaguchi, 2013, The Journal of Pharmacology and Experimental Therapeutics.